Oxular’s development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and macular degeneration, as well as programs for rare and orphan conditions, including ocular cancers and delivery of gene therapy.

The pipeline utilizes Oxular’s technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.​

Oxular’s two leading programs, OXU-001 and OXU-003, are expected to deliver Phase 2 data within two years.

Click on each program in the pipeline for an overview.

OXU-001, our lead program

A 12-Month dexamethasone* treatment for inflammatory retinal diseases, including Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) and Uveitis

The OXU-001 program is investigating the use of dexamethasone* in our sustained-release Oxuspheres formulation, with delivery to the suprachoroidal space via the Oxulumis device, in order to treat DME, RVO and Uveitis.

Phase 2 studies will commence later this year with a specific focus on DME patients.

  • The diseases
  • Patient unmet needs
  • The life-changing treatment

DME

Diabetic macular edema (DME) is a serious retinal disease that affects 24 million people globally and is the leading cause of blindness in young adults in developed countries. Read more

RVO

RVO is a blockage of a retinal vein. It is a common cause of sudden painless reduction in vision in people over 60, which affects c.16m people globally each year. 20-30% of patients experience no improvement in vision following current treatments. Read more

Uveitis

Uveitis is inflammation of the uvea (the middle layer of the eye) that causes eye pain and changes to vision, and affects c.800,000 patients annually. It can lead to complications such as glaucoma, cataracts and detached retina. 

 

A key challenge facing patients with DME is the need for frequent clinic visits (c.25 p.a.) for treatments related to their diabetes with around four of these visits directly related to DME treatment.

Drug-related side effects can also be common. The market-leading treatment results in elevated intraocular pressure (IOP) in 28% of subjects plus 68% incidence of cataracts.

Administration of the treatments are also invasive, involving penetration of the ocular cavity with a large, 22-gauge needle.  

The combination of the above can significantly reduce patient adherence to treatment regimes, and ultimate patient outcomes.

Oxular’s combined technology platforms uniquely solve the unmet needs that patients with inflammatory retinal diseases currently face.

The program technology

Oxuspheres, our proprietary drug-containing biodegradable polymer system, are used to create an adjustable, sustained release-formulation of dexamethasone. Dexamethasone is a well-known, safe, and effective treatment for inflammatory retinal diseases, including DME.

Delivery of the formulation is by Oxulumis™, our proprietary, semi-automated ocular administration device that utilizes an advantageous route of administration (the suprachoroidal space) to treat retinal diseases.

Oxulumis™is designed to deliver therapeutics via an illuminated microcatheter that allows routine, safe and accurate drug deployment to the specific tissues involved in retinal disease. Oxulumis™offers physicians a novel, less invasive, efficient in-office administration procedure.

How it transforms treatments

The sustained-release formulation has the ability to provide up to 12 months’ treatment of DME following single administration, compared to an average of c.3 months for current market leading treatments.

Significantly fewer treatments p.a. has the potential to reduce the unsustainable treatment burden on patients, clinicians, and healthcare systems, as well as assist patients in maintaining their treatment regime.

The sustained release of the drug product offers better efficacy, addressing both VEGF and inflammation, and the unmet needs of refractory patients, while offering sustained vision gain & CRT reduction.

It also offers better safety, with significantly lower rates of IOP elevation & cataracts, and no intra-ocular inflammation.

Finally, the Oxulumis device offers better delivery, with a minimally invasive, efficient office procedure that involves no penetration of the retinal tissues and reduces treatment side effects associated with intraocular delivery.

One treatment a year. Life-changing.

Scroll to Top